Business
GeoVax to Present at the Emerging Growth Conference on August 20, 2025
Company to Provide Key Updates on GEO-MVA and Its Mpox Vaccine Development Program ATLANTA, GA - August 18, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunothe...
About this update from Geovax Labs, Inc.
[{"type":"image","caption":"","headline":"GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","size":{"original":{"width":140,"height":140,"url":"https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CK3y_RQaAtNDQGf8lPQXOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140}}},{"type":"text","content":"Company to Provide Key Updates on GEO-MVA and Its Mpox Vaccine Development Program","length":82,"tagName":"p"},{"type":"text","content":"ATLANTA, GA - August 18, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced that it will present at the Emerging Growth Conference on Wednesday, August 20, 2025. This live, interactive online event will provide existing shareholders and the investment community an opportunity to hear directly from the Company's Chairman and CEO, David Dodd, and engage in a real-time Q&A session.","length":539,"tagName":"p"},{"type":"text","content":"Mr. Dodd will present from 3:40 PM to 3:50 PM Eastern Time, discussing recent progress and upcoming milestones related to GeoVax's GEO-MVA, a next-generation MVA-based Mpox/smallpox vaccine positioned to support global preparedness and stockpile strategies. GeoVax recently received favorable Scientific Advice (SA) from the European Medicines Agency (EMA), potentially allowing for a significant acceleration of the regulatory approval timeline for GEO-MVA.","length":462,"tagName":"p"},{"type":"text","content":"The Company will also highlight how its MVA platform and U.S.-based continuous cell line manufacturing position GeoVax to address critical gaps in vaccine supply diversification, pandemic readiness, and biosecurity.","length":215,"tagName":"p"},{"type":"text","content":"Register here to attend the conference and receive event updates: https://goto.webcasts.com/starthere.jsp?ei=1717088&tp_key=22f1f30884&sti=govx","length":151,"tagName":"p"},{"type":"text","content":"Participants may submit questions in advance to [email protected] or ask them live during the presentation. A replay will be...